Licensing Radiology Trials 
XTalks
SEPTEMBER 9, 2022
Magnus Medical received exclusive licensing rights to commercialize the SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) technology from Stanford University. The SAINT Neuromodulation Trial. The California-based medical device company develops brain stimulation technology to treat neuropsychiatric disorders.
pharmaphorum
MARCH 31, 2021
Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where tumours are located in the body. . billion to buy targeted radioligand therapy Lu-PSMA-617 from Endocyte , shortly after encouraging results in a phase 2 prostate cancer trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Advarra
APRIL 30, 2024
Maintaining complete and compliant documentation while managing the complex processes and interactions of clinical trial conduct is complicated. Investigator Site Files The ISF contains essential documents permitting evaluation of a clinical trial’s conduct. Remember, some staff may not need protocol-specific training. based sites.
pharmaphorum
JUNE 18, 2021
The Compliant Component Builder platform has already been put through its paces at AstraZeneca, which used it to build a new component to incorporate into one of its existing digital health tools, used for remote monitoring of patients in clinical trials. The algorithms used in healthcare are becoming more complex as well.
pharmaphorum
APRIL 7, 2021
In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially to treat tumours. That was acquired from Endocyte in 2018 in a $2.1
pharmaphorum
OCTOBER 4, 2022
On 27th September 2022, the Food and Drug Administration (FDA) issued its final guidance for industry and FDA staff clinical decision support (CDS) software, which has been anticipated since the Center for Devices and Radiological Health (CDRH) listed the guidance as a top priority for fiscal year 2022.
pharmaphorum
SEPTEMBER 30, 2022
First and most obviously is the detailed data from the Clarity AD study reported this week, which will be revealed at the Clinical Trials on Alzheimer’s Congress (CTAD) in November. There will still be much debate about the exact license granted to the drug and cost-effectiveness deliberations, according to Prof Passmore.
Expert insights. Personalized for you.
98 
Let's personalize your content